PerkinElmer, Inc. (PKI) Income Statement Analysis

See more : AirTrip Corp. (6191.T) Income Statement Analysis – Financial Results

Complete financial analysis of PerkinElmer, Inc. (PKI) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PerkinElmer, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.

You may be interested

CTT Pharmaceutical Holdings, Inc. (CTTH) Income Statement Analysis – Financial Results
Hamai Company Limited (6131.T) Income Statement Analysis – Financial Results
Transgene Biotek Limited (TRABI.BO) Income Statement Analysis – Financial Results
Nantong Acetic Acid Chemical Co., Ltd. (603968.SS) Income Statement Analysis – Financial Results
Eureka Industries Limited (EUREKAI.BO) Income Statement Analysis – Financial Results

PerkinElmer, Inc. (PKI)

Industry: Medical - Diagnostics & Research

Sector: Healthcare

Website: https://www.perkinelmer.com

About PerkinElmer, Inc.

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998	1997	1996	1995	1994	1993	1992	1991	1990	1989	1988	1987	1986	1985
Revenue	3.31B	5.07B	3.78B	2.88B	2.78B	2.26B	2.12B	2.26B	2.24B	2.17B	2.12B	1.92B	1.70B	1.81B	1.94B	1.79B	1.55B	1.47B	1.69B	1.54B	1.50B	1.33B	1.70B	1.36B	1.41B	1.46B	1.43B	1.42B	1.33B	2.70B	2.79B	2.69B	2.47B	1.65B	1.41B	1.24B	1.15B	1.16B
Cost of Revenue	1.32B	2.22B	1.67B	1.49B	1.44B	1.18B	1.10B	1.24B	1.23B	1.19B	1.15B	1.07B	945.72M	1.03B	1.11B	1.06B	918.29M	859.30M	1.01B	906.27M	904.10M	721.73M	918.43M	787.30M	991.30M	1.04B	1.01B	1.01B	957.80M	2.30B	2.39B	2.31B	2.14B	1.35B	1.11B	984.00M	935.30M	927.90M
Gross Profit	1.99B	2.85B	2.11B	1.40B	1.34B	1.07B	1.01B	1.02B	1.00B	976.97M	963.21M	850.58M	758.63M	779.79M	830.11M	724.74M	628.07M	614.54M	680.55M	628.95M	600.88M	608.33M	776.84M	575.80M	416.60M	420.70M	419.50M	407.00M	374.80M	393.20M	401.50M	382.00M	333.50M	303.80M	292.00M	251.90M	209.80M	227.20M
Gross Profit Ratio	60.08%	56.27%	55.78%	48.41%	48.27%	47.54%	47.90%	45.28%	44.90%	45.10%	45.54%	44.27%	44.51%	43.03%	42.84%	40.55%	40.62%	41.70%	40.34%	40.97%	39.93%	45.74%	45.82%	42.24%	29.59%	28.80%	29.39%	28.67%	28.13%	14.57%	14.40%	14.21%	13.48%	18.41%	20.76%	20.38%	18.32%	19.67%
Research & Development	221.62M	274.97M	205.39M	189.34M	194.00M	139.40M	124.28M	125.93M	121.14M	133.02M	132.64M	115.82M	95.41M	107.25M	108.06M	111.62M	99.72M	87.37M	87.05M	83.15M	86.45M	81.32M	86.12M	71.20M	46.00M	44.90M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	1.03B	1.23B	917.89M	815.32M	811.91M	616.17M	600.89M	598.85M	659.34M	585.85M	632.73M	628.60M	490.66M	504.70M	522.88M	444.41M	376.85M	365.46M	387.54M	386.40M	431.30M	411.15M	418.98M	327.10M	226.30M	243.40M	290.90M	284.90M	278.20M	234.60M	242.00M	223.10M	195.90M	179.90M	169.30M	151.40M	133.20M	130.10M
Other Expenses	25.26M	36.41M	-23.52M	-27.69M	-13.21M	33.59M	-3.73M	-4.80M	-5.54M	-14.84M	-2.92M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	1.25B	1.50B	1.12B	1.00B	1.01B	755.57M	725.16M	724.78M	780.48M	718.87M	765.37M	744.42M	586.07M	611.95M	630.95M	540.69M	478.31M	451.33M	503.48M	495.22M	540.87M	492.46M	592.81M	464.40M	322.70M	332.90M	331.80M	324.30M	315.00M	272.40M	278.30M	256.80M	225.80M	205.40M	193.90M	172.60M	149.60M	145.20M
Cost & Expenses	2.57B	3.72B	2.80B	2.49B	2.44B	1.94B	1.83B	1.96B	2.01B	1.91B	1.92B	1.82B	1.53B	1.64B	1.74B	1.60B	1.40B	1.31B	1.51B	1.40B	1.44B	1.21B	1.51B	1.25B	1.31B	1.37B	1.34B	1.34B	1.27B	2.58B	2.67B	2.56B	2.37B	1.55B	1.31B	1.16B	1.08B	1.07B
Interest Income	3.59M	2.24M	1.01M	1.50M	1.14M	2.57M	702.00K	673.00K	667.00K	650.00K	747.00K	1.88M	832.00K	1.04M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	103.96M	102.13M	49.71M	63.63M	66.98M	43.94M	41.53M	38.00M	36.27M	49.92M	45.79M	24.78M	15.89M	17.16M	16.88M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	455.85M	413.09M	232.02M	217.26M	179.66M	105.00M	99.97M	112.01M	116.74M	128.47M	126.87M	110.92M	89.16M	91.84M	88.31M	80.83M	69.48M	124.38M	84.34M	89.78M	96.11M	84.26M	87.72M	66.10M	50.40M	44.60M	40.90M	39.40M	36.80M	37.80M	36.30M	33.70M	29.90M	25.50M	24.60M	21.20M	16.40M	15.10M
EBITDA	1.20B	1.75B	1.21B	579.23M	503.55M	458.62M	385.13M	407.61M	336.00M	372.39M	322.53M	218.97M	262.56M	260.72M	318.07M	168.17M	153.40M	358.67M	177.07M	137.27M	219.48M	281.84M	311.28M	243.90M	82.10M	166.20M	135.90M	118.70M	168.00M	151.30M	154.30M	154.90M	127.60M	113.40M	115.80M	91.50M	57.20M	79.00M
EBITDA Ratio	36.19%	34.45%	32.00%	20.09%	18.13%	20.32%	18.21%	18.02%	15.02%	17.19%	15.25%	11.40%	15.41%	14.39%	16.42%	15.20%	14.24%	24.34%	15.80%	17.83%	14.58%	21.19%	18.36%	17.89%	5.83%	11.38%	9.52%	8.36%	12.61%	5.61%	5.53%	5.76%	5.16%	6.87%	8.23%	7.40%	5.00%	6.84%
Operating Income	742.70M	1.33B	978.58M	361.97M	323.88M	304.80M	283.07M	286.13M	210.74M	217.44M	98.54M	89.70M	153.60M	147.61M	192.97M	168.17M	153.40M	140.95M	177.07M	137.27M	24.32M	37.33M	184.03M	111.40M	93.90M	87.80M	87.70M	82.70M	59.80M	120.80M	123.20M	125.20M	107.70M	98.40M	98.10M	79.30M	60.20M	82.00M
Operating Income Ratio	22.43%	26.29%	25.87%	12.55%	11.66%	13.50%	13.38%	12.65%	9.42%	10.04%	4.66%	4.67%	9.01%	8.15%	9.96%	9.41%	9.92%	9.56%	10.49%	8.94%	1.62%	2.81%	10.86%	8.17%	6.67%	6.01%	6.14%	5.83%	4.49%	4.48%	4.42%	4.66%	4.35%	5.96%	6.98%	6.42%	5.26%	7.10%
Total Other Income/Expenses	-90.86M	-52.49M	-72.22M	-124.83M	-66.20M	-8.09M	-39.00M	-42.12M	-41.14M	-64.11M	-47.96M	-26.77M	8.38M	-16.94M	-45.61M	-16.88M	-2.67M	-41.61M	-40.32M	-56.39M	-32.87M	-3.18M	-39.54M	-66.50M	62.10M	-33.80M	-7.30M	3.40M	-76.90M	1.10M	-2.10M	-4.90M	-500.00K	1.40M	-700.00K	1.70M	12.10M	6.60M
Income Before Tax	651.84M	1.28B	906.36M	237.14M	257.68M	296.72M	244.07M	244.02M	169.60M	153.33M	50.59M	62.93M	161.98M	130.68M	147.36M	151.29M	150.74M	66.66M	136.75M	80.88M	-8.55M	34.15M	144.49M	44.90M	156.00M	54.00M	80.40M	86.10M	-17.10M	121.90M	121.10M	120.30M	107.20M	99.80M	97.40M	81.00M	72.30M	88.60M
Income Before Tax Ratio	19.68%	25.26%	23.96%	8.22%	9.28%	13.15%	11.54%	10.79%	7.58%	7.08%	2.39%	3.28%	9.50%	7.21%	7.61%	8.46%	9.75%	4.52%	8.10%	5.27%	-0.57%	2.57%	8.52%	3.29%	11.08%	3.70%	5.63%	6.07%	-1.28%	4.52%	4.34%	4.47%	4.33%	6.05%	6.93%	6.55%	6.31%	7.67%
Income Tax Expense	129.16M	347.60M	178.27M	9.39M	20.21M	139.83M	28.36M	31.33M	8.44M	-12.19M	-17.85M	62.75M	26.06M	37.93M	21.22M	17.46M	32.41M	128.00K	38.50M	25.87M	-4.42M	34.77M	58.42M	16.50M	54.00M	23.40M	25.90M	31.80M	15.00M	42.30M	33.30M	39.10M	33.20M	29.90M	28.70M	25.50M	27.40M	32.90M
Net Income	579.18M	932.16M	727.89M	227.56M	237.93M	292.63M	234.30M	212.43M	157.78M	164.81M	69.94M	6.66M	383.92M	85.60M	126.41M	131.69M	119.58M	268.11M	96.04M	52.96M	-151.94M	34.51M	90.52M	154.30M	102.00M	33.60M	60.20M	68.00M	-5.60M	59.10M	87.80M	81.20M	74.00M	69.90M	68.70M	55.50M	44.90M	55.70M
Net Income Ratio	17.49%	18.40%	19.24%	7.89%	8.56%	12.97%	11.08%	9.39%	7.05%	7.61%	3.31%	0.35%	22.53%	4.72%	6.52%	7.37%	7.73%	18.19%	5.69%	3.45%	-10.10%	2.59%	5.34%	11.32%	7.24%	2.30%	4.22%	4.79%	-0.42%	2.19%	3.15%	3.02%	2.99%	4.24%	4.89%	4.49%	3.92%	4.82%
EPS	4.59	8.12	6.52	2.06	2.13	2.67	2.14	1.89	1.40	1.49	0.61	0.07	3.34	0.74	1.07	1.11	0.96	2.07	0.75	0.42	-1.21	0.33	0.92	1.69	1.13	0.37	0.64	0.66	-0.05	0.53	0.78	0.73	0.65	0.60	0.57	0.50	0.42	0.52
EPS Diluted	4.58	8.08	6.49	2.04	2.13	2.64	2.12	1.87	1.39	1.47	0.61	0.07	3.31	0.73	1.07	1.09	0.95	2.04	0.74	0.41	-1.21	0.32	0.89	0.29	1.11	0.37	0.64	0.66	-0.05	0.53	0.78	0.73	0.65	0.60	0.57	0.50	0.42	0.52
Weighted Avg Shares Out	126.16M	116.17M	111.51M	110.83M	110.56M	109.86M	109.48M	112.51M	112.59M	112.25M	113.73M	112.98M	117.11M	116.25M	117.66M	118.64M	124.57M	129.52M	128.06M	126.09M	125.57M	104.56M	98.39M	91.30M	90.27M	91.08M	94.80M	103.03M	112.00M	112.57M	112.56M	111.23M	113.85M	116.50M	119.48M	111.00M	108.19M	107.12M
Weighted Avg Shares Out (Dil)	126.43M	116.67M	112.09M	111.50M	111.53M	110.86M	110.31M	113.32M	113.74M	113.50M	114.86M	113.86M	117.98M	116.59M	118.69M	120.81M	125.88M	131.43M	129.79M	129.17M	125.57M	107.83M	101.71M	91.30M	91.89M	91.08M	94.80M	105.98M	112.00M	112.57M	112.56M	111.23M	113.85M	116.50M	119.48M	111.00M	108.19M	107.12M

PerkinElmer Donation Helps Significantly Expand Capacity for Sickle Cell Disease Screening in Ghana

October 13, 2022businesswire.com

WALTHAM, Mass.

PerkinElmer's (PKI) New Benchtop Platform to Boost Workflows

September 27, 2022zacks.com

PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.

PerkinElmer Unveils Industry-first Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

September 26, 2022businesswire.com

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc., (NYSE: PKI), a global leader committed to innovating for a healthier world, today launched the Cellaca® PLX Image Cytometry System, a first-of-its-kind benchtop platform that enables researchers to assess multiple Critical Quality Attributes (CQAs) of cell...

PerkinElmer's (PKI) Reagent Kit Receives FDA Clearance

September 23, 2022zacks.com

PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.

PerkinElmer's Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

September 22, 2022businesswire.com

WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer's (NYSE: PKI) Oxford Immunotec today announced the U.S. Food and Drug Administration (FDA) has approved the use of the T-Cell Select™ reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic (IVD) use...

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

September 15, 2022zacks.com

PerkinElmer (PKI) continues to gain from solid product portfolio despite forex woes.

PerkinElmer, Inc. (PKI) Presents at Baird's 2022 Global Healthcare Conference (Transcript)

September 15, 2022seekingalpha.com

PerkinElmer, Inc. (NYSE:PKI ) Baird's 2022 Global Healthcare Conference September 13, 2022 10:50 AM ET Company Participants Prahlad Singh - CEO Conference Call Participants Tom Peterson - Baird Tom Peterson Thanks, everyone. Welcome. Thank you for joining.